Edinburgh Clinical Trials

MucAct

What is the clinical effectiveness and cost-effectiveness of nebulised saline in patients with chronic obstructive pulmonary disease? (MucAct COPD Trial)

We want to study whether breathing in salty water through a nebuliser can help patients with Chronic Obstructive Pulmonary Disease (COPD) cough up phlegm, make them feel better and cut down the number of chest infections. We also would like to know whether this is better than taking tablets (carbocisteine), also thought to help patients clear phlegm from the airways.

 

Chief Investigator: Professor Adam Hill 

MucAct Logo

Number and location of participating sites (by region/ country): 10-20 UK Sites

EudraCT number: 2020-001949-39

ISRCTN number:  TBC

Funder: National Institute for Health Research Health Technology Assessment Programme (NIHR HTA)

Start and End date

Of grant award: 01 June 2020

Of recruitment: Anticipated 01 Dec 2020

 

Current Status: In set up

Trial Website: No

Email: MucActCOPD@ed.ac.uk

 

GDPR Privacy Statement:

 

Sponsor: ACCORD (https://www.accord.ed.ac.uk/)

Chief Investigator:

Professor Adam Hill

Address: 102 West Port, Edinburgh, EH3 9DN

Email: adam.hill318@nhs.net

 

Trial Manager:

Jean Antonelli  

Email: MucActCOPD@ed.ac.uk

 

Research nurse: Sam Donaldson and Andrea Clarke

Email: sam.donaldson1@nhs.net

Email: andrea.clarke8@nhs.net

 

ECTU involvement: Trial management / Statistics / Health Economics / Data base